Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

PARIS, July 30 (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.